Direct targeting of SLC7A11 by miR-143-3p promotes ferroptosis and suppresses malignancy in cervical squamous cell carcinoma

Cancer is often understood as a disease of uncontrolled growth, but it is also a battle for survival within the body's own defenses. One of the body's natural ways to eliminate damaged or dangerous cells is a specific type of self-destruction known as ferroptosis. Unlike the more familiar forms of cell death that involve a cell simply shutting down or bursting, ferroptosis is driven by iron. It occurs when iron builds up inside a cell and triggers a chain reaction that damages the cell's fatty membranes, essentially causing the cell to rust from the inside out until it can no longer function. Many cancer cells are clever enough to build strong shields against this rusting process, allowing them to survive and spread. Understanding how these cells build their shields, and how to break them, offers a new path for treatment.

In the context of cervical cancer, a disease that remains a leading cause of death among women worldwide, researchers have been searching for the specific molecular switches that allow these cells to resist ferroptosis. A team of scientists at Nanjing Medical University and Nanjing University of Chinese Medicine recently investigated this question, focusing on the earliest stages of cervical squamous cell carcinoma. They discovered a precise mechanism where a tiny piece of genetic material, known as a microRNA, normally acts as a brake on a protein that protects cancer cells from rusting. When this brake is lost, the cancer cells become too strong, resisting death and becoming more aggressive.

The researchers began their investigation by comparing the genetic makeup of cervical tissue from three women with early-stage cancer against tissue from three healthy women. Using advanced sequencing technology, they scanned the entire genetic code to see which genes were turned on or off. They found that the cancer tissues were filled with genetic changes related to how cells handle stress and move around. Among these changes, one gene stood out: SLC7A11. This gene produces a protein that acts as a gatekeeper, bringing in nutrients that help the cell neutralize the damaging effects of iron and prevent it from rusting. In the cancer samples, this protective gene was turned on to a level more than five times higher than in healthy tissue. The cancer cells were essentially overloading their defenses to avoid being destroyed by ferroptosis.

To understand why this gene was so active, the team looked for the genetic switches that control it. They identified a small molecule called miR-143-3p, which functions like a dimmer switch for gene expression. In healthy tissue, this molecule is present in normal amounts, but in the cancer samples, it was significantly reduced, dropping to less than a quarter of its usual level. The researchers predicted that this missing molecule was supposed to bind directly to the SLC7A11 gene to keep it in check. To test this, they performed a series of experiments in the laboratory using cervical cancer cells. When they artificially added more of the miR-143-3p molecule back into the cells, the levels of the protective SLC7A11 protein dropped. Conversely, when they blocked the molecule, the protective protein surged.

The team then confirmed that this interaction was direct. They engineered a test where the cancer cells were exposed to a light-producing signal attached to the SLC7A11 gene. When the miR-143-3p molecule was present, the light dimmed, proving that the molecule was physically binding to the gene and silencing it. This confirmed that miR-143-3p is the direct regulator that normally keeps the protective shield in check.

The most critical part of the study was observing what happened when the cancer cells were forced to rely on this new balance. When the researchers increased the levels of miR-143-3p, the cancer cells began to undergo ferroptosis. They accumulated iron, their internal fats began to break down, and they died. Crucially, the researchers tested whether the cells were dying from other causes, such as a standard programmed shutdown or a violent rupture. They found that inhibitors of those other death pathways did not stop the cells from dying, but an inhibitor of ferroptosis did. This proved that the cells were indeed dying from rusting, not from any other form of cell death. Furthermore, the cells that had their protective shield lowered by miR-143-3p also showed a reduced ability to change their shape and move, a process known as the epithelial-mesenchymal transition, which cancer cells use to spread to other parts of the body.

The study also examined what happens when the cancer cells are attacked by a drug designed to induce ferroptosis. When the researchers blocked the miR-143-3p molecule, the cancer cells became much more resistant to the drug, surviving the attack that would have killed them. This suggests that the loss of miR-143-3p is a key reason why these cancer cells can survive and thrive. The findings indicate that the cancer cells in the early stages of cervical squamous cell carcinoma have evolved to silence this specific genetic brake, allowing them to build up their defenses against iron-induced death.

While the study was conducted in a controlled laboratory setting using cell cultures and a small number of patient tissue samples, the results provide a clear map of a specific biological pathway. The researchers noted that their work was limited to these initial models and that further studies in living organisms would be needed to confirm how this mechanism plays out in a full human body. However, the evidence strongly suggests that the relationship between miR-143-3p and SLC7A11 is a fundamental part of how cervical cancer develops its resistance to natural cell death. By identifying this specific axis, the study highlights a potential new target for therapy. Restoring the levels of miR-143-3p or blocking the SLC7A11 protein could potentially force these cancer cells to lower their shields, making them vulnerable to the body's natural rusting process once again. This approach offers a promising direction for future treatments that could help overcome the resistance that currently limits the success of cancer therapies.